The diabetic retinopathy market is projected to expand USD 6.7 billion at a CAGR 6.4% during the forecast period 2023-2032. Diabetes mellitus (DM) is a long-term condition defined by high blood glucose levels caused by insufficient insulin synthesis or insulin resistance. Diabetic retinopathy is a consequence of diabetes that results in retinal damage. This illness causes vision loss and eventually blindness. Diabetic retinopathy has a significant economic impact on healthcare systems, in addition to the direct impact on patients' quality of life. Diabetic retinopathy is the most common cause of legal blindness in those aged 20 to 74.
An increase in diabetes prevalence, a rise in the senior population, an increase in the incidence of diabetes-related blindness, and a greater focus on early identification to manage diseases are driving the market. As new technology and minimally painful laser procedures with quick recovery become accessible, patients' willingness to undergo surgical treatments is expected to rise. Furthermore, new ophthalmic gadgets and systems have simplified diagnostic and surgical procedures, which has aided the industry's expansion.
The Global Diabetic Retinopathy Market has been segmented based on type, treatment, end-user, and region.
The market, based on type, has been segmented into non-proliferative and proliferative.
The market, based on treatment, has been segmented into anti-VEGF drugs, laser photocoagulation, vitreoretinal surgery, and steroid injection.
The market, based on end-user, has been segmented into hospitals, ambulatory surgical centers, and others.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diabetic retinopathy market in the Americas has further segmented into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic retinopathy industry has been sub-divided into Western Europe and Eastern Europe. Western Europe has further the as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diabetic retinopathy Industry in the Middle East & Africa has been divided into the Middle East and Africa.
F.Hoffmann-La Roche AG,
Regeneron Pharmaceuticals, Inc.,
Alimera Sciences,
Ampio Pharmaceuticals Inc.,
Aurolab, Allergan PLC,
others.
Diabetic Retinopathy Global Market Share by Region, 2018 (%)
Source: World Health Organization (WHO)
The market in the Americas is expected to dominate the diabetic retinopathy market due to the presence of major established players in the region and increasing R&D expenses.
Europe is expected to hold the second-largest position in the diabetic retinopathy global market. This can be attributed to the presence of a well-established healthcare system and an increased prevalence of diabetes.
Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing pool of population and increasing awareness about the products.
The diabetic retinopathy market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.
A team of University of Pennsylvania researchers discovered that taking a medicine used to lower cholesterol levels in the bloodstream can minimize the likelihood of developing proliferative diabetic retinopathy (PDR) from non-proliferative diabetic retinopathy (NPDR). The researchers talked about their cohort study, which included 5,835 patients who took fenofibrate and 144,417 who didn't, and what they learned regarding the drug's efficacy in reducing DME, PDR, and vision-threatening diabetic retinopathy (VTDR).
iHealthScreen Inc. has announced that the iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), and Glaucoma Suspect was approved by the Australian Health. The AI Eye Screening System does completely automated diabetic retinopathy, age-related macular degeneration, and glaucoma suspect screening. Primary care and specialized practices can use the iPredictTM System to effectively and quickly screen diabetic patients for DR, persons over 50 for AMD, and people with a suspected risk of glaucoma.
| Report Attribute/Metric | Details |
| Market Size 2022 | 33.84(USD Billion) |
| Market Size 2023 | 35.92(USD Billion) |
| Market Size 2032 | 61.4(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 6.14% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lumentum Holdings, ZTE Corporation, Corning Incorporated, Ciena Corporation, Nokia, Juniper Networks, ADVA Optical Networking, NEC Corporation, Huawei Technologies, Fujitsu, Broadcom Inc., Ribbon Communications, Infinera Corporation, Mitsubishi Electric, Cisco Systems |
| Segments Covered | Technology, Components, Application, End Use, Regional |
| Key Market Opportunities | 5G network expansion, Increased cloud service demand, Rise in IoT applications, Growth in data center investments, Enhanced security solutions. |
| Key Market Dynamics | Growing demand for bandwidth, Increasing cloud services, Adoption of 5G technology, Rise in IoT connections, Need for network modernization |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Diabetic Retinopathy Market Highlights:
Frequently Asked Questions (FAQ) :
The valuation was USD 6.7 billion valuation in 2032.
The projected CAGR 6.4% during the forecast period of 2023-2032.
F.Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Ampio Pharmaceuticals Inc., Aurolab, Allergan PLC, Abbott Laboratories, and others. are key players of the Diabetic Retinopathy Market
The treatments are vitreoretinal surgery, laser photocoagulation, anti-VEGF drugs, and steroid injection.
Ambulatory surgical centers, hospitals, and others have been recorded as a part of the market report.
The types included in the report are non-proliferative and proliferative.
The diabetic retinopathy market is projected to expand USD 6650 Mn at a 6.50% CAGR during the forecast period 2022-2030.
$6650 million
6.50%
North America
2022-2030
Team Lead - Research she holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
